Nkarta, Inc. NKTX

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
67/100
Moderate

Ranked against 712 peers in Biotechnology

About Nkarta, Inc.

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated … Full NKTX analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 1.00), suggesting sticky customer base.
  • Strong Liquidity Buffer Liquidity position is strong (score 0.86), providing operational cushion.

Key risks

  • Weak or Negative Cash Flow Cash generation is weak (score 0.00), limiting financial flexibility.
  • Inconsistent Cash Generation Cash generation is inconsistent (score 0.00), indicating operational challenges.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where NKTX ranks in Biotechnology

Nkarta, Inc. ranks #54 of 713 scored companies in Biotechnology by moat score — the top 8%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
50 Amicus Therapeutics, Inc. FOLD 68/100 Moderate
51 Minerva Neurosciences, Inc NERV 68/100 Moderate
52 Stoke Therapeutics, Inc. STOK 68/100 Moderate
53 Apellis Pharmaceuticals, Inc. APLS 68/100 Moderate
54 Nkarta, Inc. NKTX 67/100 Moderate
55 Ultragenyx Pharmaceutical Inc. RARE 67/100 Moderate
56 OS Therapies Incorporated OSTX 67/100 Moderate
57 Xeris Biopharma Holdings, Inc. XERS 67/100 Moderate
58 Apogee Therapeutics, Inc. APGE 67/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How NKTX scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 100 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 52 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 70 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding NKTX's moat

What is Nkarta, Inc.'s moat score?

Nkarta, Inc. (NKTX) scores 67 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #54 of 713 scored companies in Biotechnology, the top 8%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (100/100) and its weakest is Capital Efficiency (52/100).

How does Nkarta, Inc. compare with other Biotechnology companies?

Nkarta, Inc. ranks #54 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Apellis Pharmaceuticals, Inc. (APLS) at 68 just above it and Ultragenyx Pharmaceutical Inc. (RARE) at 67 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Nkarta, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Nkarta, Inc.?

The Corporate Default template measures 6 defenses, and NKTX scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (100), Capital Efficiency (52), Resilience (70), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000